NS

Neelima Singuru

Active Director Director DIN 08556762
DIN 08556762 First appointment Sep 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2019
Shareholding value •••• Premium profile

About Neelima Singuru

Data last updated:

Neelima Singuru is a Director at Humaniqe Biopharmaceuticals Private Limited (since 2019). The company operates in Pharma. Humaniqe Biopharmaceuticals Private Limited reported revenue of ₹7.82 Cr (FY 2023).

DIN 08556762
Primary Designation Director
Industry Pharma
First Appointment 06 Sep 2019
Oldest Company Age 7 yrs
Largest company Humaniqe Biopharmaceuticals Private Limited · ₹7.82 Cr (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Sep 20192019₹7.82 Cr (FY 2023)Active

Board colleagues of Neelima Singuru

Directorship timeline

Open interactive timeline →
Humaniqe Biopharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Neelima Singuru

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neelima Singuru

Neelima Singuru currently holds 1 directorship: Humaniqe Biopharmaceuticals Private Limited (Director, since 06 Sep 2019, revenue ₹7.82 Cr (FY 2023)).

Neelima Singuru was first appointed on 06 Sep 2019 as Director at Humaniqe Biopharmaceuticals Private Limited.

The current boards of Neelima Singuru's companies include Modalavalasa Sireesha (Humaniqe Biopharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available